Germany still not keen on Eisai's Halaven after reassessment
This article was originally published in Scrip
Executive Summary
Germany's IQWiG has improved its opinion of Eisai's breast cancer drug Halaven (eribulin) – but only slightly. In a reassessment of the product, the German health technology assessment institute was still lukewarm about the drug's additional benefit.